Larisa Gubareva, M.D., Ph.D., and colleagues at the CDC’s National Center for Infectious and Respiratory Diseases in Atlanta, report that samples from 13 (20 percent) of the 64 patients infected with the virus in the United States as of April 28 were tested for antiviral medication resistance.
Cross-resistance to the adamantane class of anti-influenza drugs was confirmed in all 13 samples due to the presence of the S31N mutation in the virus’ M2 protein, but all 13 samples were found to be susceptible to oseltamivir and zanamivir, as well as peramivir and A-315675, new neuraminidase inhibitors currently undergoing clinical trials, the researchers note.
“Compared with M2 blockers, neuraminidase inhibitors previously exhibited lower frequency of antiviral resistance during therapeutic use. However, during the 2007-2008 influenza season, emergence and transmission of oseltamivir-resistant A (H1N1) viruses…was simultaneously detected in several countries in the Northern Hemisphere,” notes a related editorial. “As a result, the World Health Organization Global Influenza Surveillance Network and CDC have emphasized the urgent need for close monitoring of resistance to neuraminidase inhibitors.”
CLINIC FOR CHILDREN
JL Taman Bendungan Asahan 5 Jakarta Indonesia 102010
phone : 62(021) 70081995 – 5703646
Clinical and Editor in Chief :
DR WIDODO JUDARWANTO
email : email@example.com
Copyright © 2009, Clinic For Children Information Education Network. All rights reserved.